A drug called Xiaflex is being studied as a possible treatment.
In June 2012, Auxilium Pharmaceuticals, the drug’s manufacturer, announced the results of two Phase III trials for Xiaflex. This phase tests the drug for effectiveness and helps researchers understand its side effects.
In one trial, the men who took Xiaflex saw their curvature decrease by 38% compared to 21% for the men who took a placebo. In the other trial, curvature decreased by 31% for the men who took Xiaflex. Those who took the placebo had a 15% curvature reduction.
The men who took Xiaflex also said they had less distress and less pain after treatment.
Xiaflex is given as an injection into the penis. A doctor may also manipulate the penis to break up the plaques.
Side effects of Xiaflex are accumulating blood, pain, and swelling at the injection site.
Auxilium plans to apply for approval from the U.S. Food and Drug Administration (FDA) by the end of 2012. This approval would allow the drug to be marketed as a treatment for Peyronie’s disease in the United States.